phenytoin has been researched along with Glycogen Storage Disease Type I in 1 studies
Glycogen Storage Disease Type I: An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jubiz, W | 1 |
| Rallison, ML | 1 |
1 other study available for phenytoin and Glycogen Storage Disease Type I
| Article | Year |
|---|---|
Diphenylhydantoin treatment of glycogen storage diseases.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Glucose-6-Phosphatase; Glucosidases; Glucosyltra | 1974 |